title: Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practice.
abstract: The increasing prevalence of diabetes presents one of the greatest challenges to healthcare provision in modern times, with the cost of treating diabetes and its related complications representing a significant proportion of healthcare expenditure. In recent years, many new therapeutic entities have been developed with the aim of improving glycemic control, and thus slowing the development of micro- and macrovascular complications. Insulin degludec is a new-generation basal insulin analog with an ultra-long duration of action and low day-to-day and hour-to-hour intrapatient variability in blood glucose-lowering action. In this review, we consider evidence from clinical trials and real-world studies demonstrating the clinical benefits and cost-effectiveness of insulin degludec and its potential for improving patient care.
authors.affiliation: University Hospital Llandough, Penlan Road, Penarth, Cardiff CF64 2XX, UK.
authors.forename: Marc
authors.initials: M
authors.lastname: Evans
authors.affiliation: Swansea Centre for Health Economics, University of Swansea, Singleton Park, Swansea, UK.
authors.forename: Phil
authors.initials: P
authors.lastname: McEwan
keywords: analog; cost–effectiveness; diabetes; flexible dosing; hypoglycemia; insulin degludec; real-world studies